



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

## Operations Office

---

DATE: January 14, 2011

TO: Primary PIs, Primary CRAs

FROM: Steven R. Alberts, MD  
Protocol Chair  
Linda S. Long  
Research Protocol Specialist

SUBJECT: N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma

This is a reminder that the Phase I portion of N0745 has been completed and the Phase II portion of the clinical trial is **now open** to accrual. N0745 is an important trial for us and builds on ongoing research activities in NCCTG. Patients who are potentially eligible and are interested in participating will be randomized to either Arm B (sorafenib + bevacizumab) or Arm C (sorafenib alone) for treatment. The completed Phase I portion of the trial (Arm A) established the appropriate doses for the two drug combination based on the observed adverse events to be sorafenib 200 mg BID and bevacizumab 2.5 mg/kg every 2 weeks.. As a reminder, in this trial the bevacizumab is provided to patients free of charge. I would encourage you to consider this trial for your patients with HCC.

Please contact either of us if you have any questions at [alberts.steven@mayo.edu](mailto:alberts.steven@mayo.edu) or [long.linda@mayo.edu](mailto:long.linda@mayo.edu).